Patents Assigned to Pfizer
  • N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
    Patent number: 9145416
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: September 29, 2015
    Assignee: Pfizer Inc.
    Inventors: Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
  • Sulfonamide compounds
    Patent number: 9145407
    Abstract: The invention relates to new sulfonamide Nav1.7 inhibitors and pharmaceutically acceptable salts thereof, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: September 29, 2015
    Assignees: Pfizer Limited, Icagen, Inc.
    Inventors: Christopher John Markworth, Brian Edward Marron, David James Rawson, Robert Ian Storer, Nigel Alan Swain, Christopher William West, Shulan Zhou
  • Triazine derivatives
    Patent number: 9145427
    Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: September 29, 2015
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Byrce Tuttle, Patrick Robert Verhoest
  • ANTI-IL-13 RECEPTOR ALPHA 2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20150266962
    Abstract: Disclosed herein are anti-IL-13-R?2 antibodies and antibody drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: October 30, 2013
    Publication date: September 24, 2015
    Applicant: Pfizer Inc.
    Inventors: Dangshe Ma, Fang Jin, Lioudmila Gennadievna Tchistiakova, Puja Sapra
  • Glucagon Receptor Modulators
    Publication number: 20150266861
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Application
    Filed: June 5, 2015
    Publication date: September 24, 2015
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Mary Theresa Didiuk, Kevin James Filipski, Angel Guzman-Perez, Jeffrey Allen Pfefferkorn, Benjamin Dawson Stevens, Meihua Mike Tu
  • GLUCAGON RECEPTOR MODULATORS
    Publication number: 20150266859
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Application
    Filed: June 4, 2015
    Publication date: September 24, 2015
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Mary Theresa Didiuk, Kevin James Filipski, Angel Guzman-Perez, Esther Cheng Yin Lee, Jeffrey Allen Pfefferkorn, Benjamin Dawson Stevens, Meihua Mike Tu
  • N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
    Patent number: 9139587
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: September 22, 2015
    Assignee: Pfizer Inc.
    Inventors: Scott William Bagley, David Andrew Griffith, Daniel Wei-Shung Kung
  • Heteroaromatic compounds and their use as dopamine D1 ligands
    Patent number: 9139561
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: September 22, 2015
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
  • Cytotoxic peptides and antibody drug conjugates thereof
    Patent number: 9138486
    Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: September 22, 2015
    Assignee: Pfizer Inc.
    Inventors: Matthew David Doroski, Andreas Maderna, Christopher John O'Donnell, Chakrapani Subramanyam, Beth Vetelino, Russell George Dushin, Pavel Strop, Edmund Idris Graziani
  • Quinolinyl glucagon receptor modulators
    Patent number: 9139538
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: September 22, 2015
    Assignee: Pfizer Inc.
    Inventors: Mary Didiuk, Kevin J. Filipski, Angel Guzman-Perez, Esther C. Lee, Jeffrey A. Pfefferkorn, Benjamin Stevens, Meihua Tu
  • Chemical Compounds
    Publication number: 20150259327
    Abstract: The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or a pharmaceutically acceptable salt thereof: to compositions containing them, to processes for their preparation and to intermediates used in such processes, and to methods of treatment, wherein R1, R2, R3, R4, R5 and R6 are as defined in the description.
    Type: Application
    Filed: May 27, 2015
    Publication date: September 17, 2015
    Applicant: PFIZER LIMITED
    Inventors: Robert Ian Storer, Nigel Alan Swain, Robert McKenzie Owen
  • DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS
    Publication number: 20150259323
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Application
    Filed: March 10, 2015
    Publication date: September 17, 2015
    Applicant: PFIZER INC.
    Inventors: SHAWN CABRAL, KENTARO FUTATSUGI, DAVID HEPWORTH, KIM HUARD, DANIEL WEI-SHUNG KUNG, SUVI TUULA MARJUKKA ORR, KUN SONG
  • Macrocyclic derivatives for the treatment of diseases
    Patent number: 9133215
    Abstract: The invention relates to compounds of formula (?) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: September 15, 2015
    Assignee: Pfizer Inc.
    Inventors: Simon Bailey, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal, Robert Louis Hoffman, Qinhua Huang, Ted William Johnson, Robert Steven Kania, John Charles Kath, Phuong Thi Quy Le, Michele Ann McTigue, Cynthia Louise Palmer, Paul Francis Richardson, Neal William Sach
  • Heteroaromatic compounds and their use as dopamine D1 ligands
    Patent number: 9133190
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: September 15, 2015
    Assignee: PFIZER INC.
    Inventors: Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Chakrapani Subramanyam, Lei Zhang
  • Tropomyosin-Related Kinase Inhibitors
    Publication number: 20150250785
    Abstract: The present invention relates to compounds of Formula (IA) and (IB) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: September 26, 2013
    Publication date: September 10, 2015
    Applicant: Pfizer Limited
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, Sarah Elizabeth Skerratt
  • Pyrrolo[3,2-C]Pyridine Tropomyosin-Related Kinase Inhibitors
    Publication number: 20150246912
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: September 26, 2013
    Publication date: September 3, 2015
    Applicant: Pfizer Limited
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, David Graham Brown, Karl Richard Gibson, Wolfgang Klute, Inaki Morao, Kiyoyuki Omoto, Thomas Ryckmans, Yogesh Sabnis, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • Cancer treatment
    Patent number: 9119839
    Abstract: The present invention relates to methods of treating cancer, such as melanoma, by administering a CTLA4 antagonist to a subject with a serum C-Reactive Protein (CRP) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum CRP concentration in a subject, and then administering a CTLA4 antagonist if the CRP concentration is less than or equal to a certain amount. The invention further relates to, among other things, the use of serum CRP concentration as a predictive factor for a subject's response to a cancer treatment.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: September 1, 2015
    Assignee: Pfizer Inc.
    Inventors: Bo Huang, Margaret Ann Marshall
  • Azabenzimidazole compounds
    Patent number: 9120788
    Abstract: The present invention is directed to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: September 1, 2015
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Patrick Robert Verhoest, Nandini Chaturbhai Patel, Matthew Merrill Hayward
  • BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS
    Publication number: 20150239842
    Abstract: This invention relates to compounds of general formula (I), in which R1, R2, R6, U, V, W, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and salts, and to methods of using such compounds, salts and compositions.
    Type: Application
    Filed: September 16, 2013
    Publication date: August 27, 2015
    Applicant: PFIZER INC.
    Inventors: Martin Paul Edwards, Robert Arnold Kumpf, Pei-Pei Kung, Indrawan James Mcalpine, Eugene Yuanjin Rui, Scott Channing Sutton, John Howard Tatlock, Martin James Wythes
  • Process for the Preparation of Voriconazole and Analogues Thereof
    Publication number: 20150239867
    Abstract: The present invention provides a process for preparing a compound of formula: (Formula XI and XII) (XI) (XII) wherein X, Y, Z, A, B and E are as defined herein, by reacting a compound of formula: (Formula XIII) (XIII) with a compound of formula: (Formula XIV and XV) (XIV) (XV) respectively, in the presence of a transition metal catalyst, a ligand suitable for use with 15 the catalyst and a reducing agent. The invention also provides novel intermediates.
    Type: Application
    Filed: October 8, 2013
    Publication date: August 27, 2015
    Applicant: Pfizer Ireland Pharmaceuticals
    Inventors: Adam James Musgrave Burrell, Padraig Mary O'Neill, Alan John Pettman